- Clinical Diabetes & Therapeutics
- Nonalcoholic Fatty Liver Disease and Diabetes: Part II: Treatment
-
Kyung-Soo Kim, Byung-Wan Lee, Yong Jin Kim, Dae Ho Lee, Bong-Soo Cha, Cheol-Young Park
-
Diabetes Metab J. 2019;43(2):127-143. Published online April 15, 2019
-
DOI: https://doi.org/10.4093/dmj.2019.0034
-
-
10,242
View
-
182
Download
-
29
Web of Science
-
38
Crossref
-
Abstract
PDF PubReader
Nonalcoholic fatty liver disease (NAFLD) and diabetes are common metabolic disorders that are often comorbid conditions. Among many proposed treatments, weight reduction is the only approved option for NAFLD to date. However, it is not easy to maintain weight loss by lifestyle modification alone; pharmacological treatments are helpful in this regard. Although many drugs have been investigated, pioglitazone could be a first-line therapy in patients with NAFLD and diabetes. Many more drugs are currently being developed and investigated, and it is likely that combination strategies will be used for future treatment of NAFLD and diabetes. Attention should be paid to the management of NAFLD and diabetes and efforts should be made to intervene early and individualize treatment of NAFLD in patients with diabetes.
-
Citations
Citations to this article as recorded by 
- The Triad of Risk: Linking MASLD, Cardiovascular Disease and Type 2 Diabetes; From Pathophysiology to Treatment
Eleni Michalopoulou, John Thymis, Stamatios Lampsas, George Pavlidis, Konstantinos Katogiannis, Dimitrios Vlachomitros, Eleni Katsanaki, Gavriella Kostelli, Sotirios Pililis, Loukia Pliouta, Aikaterini Kountouri, Ioannis S. Papanikolaou, Vaia Lambadiari, Journal of Clinical Medicine.2025; 14(2): 428. CrossRef - Association of non-alcoholic fatty liver disease with cardiovascular disease and all cause death in patients with type 2 diabetes mellitus: nationwide population based study
Kyung-Soo Kim, Sangmo Hong, Kyungdo Han, Cheol-Young Park BMJ.2024; : e076388. CrossRef - The Efficacy of Empagliflozin in Combination with Pioglitazone on the Improvement of Fatty Liver Disease in Patients with Type 2 Diabetes
Morteza Aghajanpoor, Mehrzad Gholampourdehaki, Reza Mosaed, Iraj Mirzaii-Dizgah, Afsaneh Vosughi Annals of Military and Health Sciences Research.2024;[Epub] CrossRef - Research Progress of Traditional Chinese Medicine and Western Medicine on Non-Alcoholic Fatty Liver Disease
强江 郭 Advances in Clinical Medicine.2024; 14(03): 561. CrossRef - Liver and cardiovascular disease outcomes in metabolic syndrome and diabetic populations: Bi-directional opportunities to multiply preventive strategies
Alhussain Yasin, Madison Nguyen, Angad Sidhu, Priyanka Majety, Jared Spitz, Amon Asgharpour, Mohammad S. Siddiqui, Laurence S. Sperling, Arshed A. Quyyumi, Anurag Mehta Diabetes Research and Clinical Practice.2024; 211: 111650. CrossRef - Effect of ipragliflozin on liver enzymes in type 2 diabetes mellitus: a meta-analysis of randomized controlled trials
Rizwana Parveen, Shadan Hussain, Sparsh Saini, Parvej Khan, Nilanjan Saha, Nidhi Expert Opinion on Pharmacotherapy.2024; 25(7): 925. CrossRef - Effect of aerobic training with silymarin consumption on glycemic indices and liver enzymes in men with type 2 diabetes
Keyvan Ghalandari, Mojtaba Shabani, Ali Khajehlandi, Amin Mohammadi Archives of Physiology and Biochemistry.2023; 129(1): 76. CrossRef - Metabolic Dysfunction-Associated Fatty Liver Disease and Mortality: A Population-Based Cohort Study
Kyung-Soo Kim, Sangmo Hong, Hong-Yup Ahn, Cheol-Young Park Diabetes & Metabolism Journal.2023; 47(2): 220. CrossRef - Comparative antihypertensive efficacy of combinations of azilsartan medoxomil or olmesartan medoxomil with amlodipine in patients with arterial hypertension, type 2 diabetes mellitus and non-alcoholic fatty liver disease
I. А. Lukonin, V. V. Skibitsky, A. V. Fendrikova, A. V. Skibitsky, I. A. Antipov South Russian Journal of Therapeutic Practice.2023; 4(1): 68. CrossRef - An Ethyl Acetate Extract of Eryngium carlinae Inflorescences Attenuates Oxidative Stress and Inflammation in the Liver of Streptozotocin-Induced Diabetic Rats
Cristian M. Trejo-Hurtado, Cinthia I. Landa-Moreno, Jenaro Lemus-de la Cruz, Donovan J. Peña-Montes, Rocío Montoya-Pérez, Rafael Salgado-Garciglia, Salvador Manzo-Avalos, Christian Cortés-Rojo, Juan Luis Monribot-Villanueva, José Antonio Guerrero-Analco, Antioxidants.2023; 12(6): 1235. CrossRef - Pharmacogenetics of glucagon-like peptide-1 agonists in the treatment of type 2 diabetes mellitus
Iu.G. Samoilova, A.E. Stankova, M.V. Matveeva, O.E. Vaizova, D.V. Podchinenova, D.A. Kudlay, T.A. Filippova, I.R. Grishkevich Profilakticheskaya meditsina.2023; 26(12): 95. CrossRef - Obesity is an important determinant of severity in newly defined metabolic dysfunction-associated fatty liver disease
Ji Hye Huh, Kwang Joon Kim, Seung Up Kim, Bong-Soo Cha, Byung-Wan Lee Hepatobiliary & Pancreatic Diseases International.2022; 21(3): 241. CrossRef - Triglyceride and glucose index is a simple and easy‐to‐calculate marker associated with nonalcoholic fatty liver disease
Kyung‐Soo Kim, Sangmo Hong, Hong‐Yup Ahn, Cheol‐Young Park Obesity.2022; 30(6): 1279. CrossRef - Evaluating Triglyceride and Glucose Index as a Simple and Easy-to-Calculate Marker for All-Cause and Cardiovascular Mortality
Kyung-Soo Kim, Sangmo Hong, You-Cheol Hwang, Hong-Yup Ahn, Cheol-Young Park Journal of General Internal Medicine.2022; 37(16): 4153. CrossRef - Pharmacological Treatment of Nonalcoholic Fatty Liver Disease: Antidiabetic Agents
Kyung-Soo Kim The Journal of Korean Diabetes.2022; 23(2): 83. CrossRef - Efficacy and mechanism of Jiedu Tongluo Tiaogan Formula in treating type 2 diabetes mellitus combined with non-alcoholic fatty liver disease: Study protocol for a parallel-armed, randomized controlled trial
Jinghan Xu, Chunli Piao, Yue Qu, Tianjiao Liu, Yuting Peng, Qi Li, Xiaohua Zhao, Pei Li, Xuemin Wu, Yawen Fan, Binqin Chen, Jie Yang Frontiers in Pharmacology.2022;[Epub] CrossRef - Intestinal microbiota in the treatment of metabolically associated fatty liver disease
Ji-Shuai Wang, Jin-Chun Liu World Journal of Clinical Cases.2022; 10(31): 11240. CrossRef - Efficiency of combined antihypertensive pharmacotherapy in patients with arterial hypertension, combined with type 2 diabetes mellitus and non-alcoholic fatty liver disease
I. A. Lukonin, V. V. Skibitsky, A. V. Fendrikova, I. I. Pavlyuchenko, K. Yu. Lazarev, F. A. Kovalenko Systemic Hypertension.2022; 19(1): 31. CrossRef - Diosgenin Ameliorated Type II Diabetes-Associated Nonalcoholic Fatty Liver Disease through Inhibiting De Novo Lipogenesis and Improving Fatty Acid Oxidation and Mitochondrial Function in Rats
Yujie Zhong, Zhiman Li, Ruyi Jin, Yanpeng Yao, Silan He, Min Lei, Xin Wang, Chao Shi, Li Gao, Xiaoli Peng Nutrients.2022; 14(23): 4994. CrossRef - Pluchea indica Leaf Extract Alleviates Dyslipidemia and Hepatic Steatosis by Modifying the Expression of Lipid Metabolism-Related Genes in Rats Fed a High Fat-High Fructose Diet
Patcharin Singdam, Jarinyaporn Naowaboot, Laddawan Senggunprai, Kampeebhorn Boonloh, Patchareewan Pannangpetch Preventive Nutrition and Food Science.2022; 27(4): 384. CrossRef - NAFLDin type 2 diabetes mellitus: Still many challenging questions
Simona Cernea, Itamar Raz Diabetes/Metabolism Research and Reviews.2021;[Epub] CrossRef - Umbilical Cord-Mesenchymal Stem Cell-Conditioned Medium Improves Insulin Resistance in C2C12 Cell
Kyung-Soo Kim, Yeon Kyung Choi, Mi Jin Kim, Jung Wook Hwang, Kyunghoon Min, Sang Youn Jung, Soo-Kyung Kim, Yong-Soo Choi, Yong-Wook Cho Diabetes & Metabolism Journal.2021; 45(2): 260. CrossRef - Comparative Efficacy of Lobeglitazone Versus Pioglitazone on Albuminuria in Patients with Type 2 Diabetes Mellitus
Kyung-Soo Kim, Sangmo Hong, Hong-Yup Ahn, Cheol-Young Park Diabetes Therapy.2021; 12(1): 171. CrossRef - Diabetes Mellitus and Non-Alcoholic Fatty Liver Disease: Diagnosis and Treatment
Sook Jung Lee, Byung-Wan Lee The Journal of Korean Diabetes.2021; 22(1): 38. CrossRef - Patient Management in Non-Alcoholic Fatty Liver Disease and Type 2 Diabetes Mellitus
A. E. Bagriy, A. D. Zubov, M. V. Khomenko, E. S. Mikhailichenko, E. A. Pylaeva, N. A. Khaustova, E. V. Bryukhovetskaya Russian Journal of Gastroenterology, Hepatology, Coloproctology.2021; 31(2): 14. CrossRef - NAFLD and its link with diabetes: Why we should be worried
Louise Cremonesini, Emma Harkin Independent Nurse.2021; 2021(8): 20. CrossRef - Albuminuria Is Associated with Steatosis Burden in Patients with Type 2 Diabetes Mellitus and Nonalcoholic Fatty Liver Disease
Eugene Han, Mi Kyung Kim, Byoung Kuk Jang, Hye Soon Kim Diabetes & Metabolism Journal.2021; 45(5): 698. CrossRef - Fatty liver index and development of cardiovascular disease in Koreans without pre-existing myocardial infarction and ischemic stroke: a large population-based study
Jun Hyung Kim, Jin Sil Moon, Seok Joon Byun, Jun Hyeok Lee, Dae Ryong Kang, Ki Chul Sung, Jang Young Kim, Ji Hye Huh Cardiovascular Diabetology.2020;[Epub] CrossRef - Novel antisense inhibition of diacylglycerol O-acyltransferase 2 for treatment of non-alcoholic fatty liver disease: a multicentre, double-blind, randomised, placebo-controlled phase 2 trial
Rohit Loomba, Erin Morgan, Lynnetta Watts, Shuting Xia, Lisa A Hannan, Richard S Geary, Brenda F Baker, Sanjay Bhanot The Lancet Gastroenterology & Hepatology.2020; 5(9): 829. CrossRef - Hepatic fibrosis is associated with total proteinuria in Korean patients with type 2 diabetes
Eugene Han, Yongin Cho, Kyung-won Kim, Yong-ho Lee, Eun Seok Kang, Bong-Soo Cha, Byung-wan Lee Medicine.2020; 99(33): e21038. CrossRef - Metabolic liver disease in diabetes – From mechanisms to clinical trials
Bedair Dewidar, Sabine Kahl, Kalliopi Pafili, Michael Roden Metabolism.2020; 111: 154299. CrossRef - Managing NAFLD in Type 2 Diabetes: The Effect of Lifestyle Interventions, a Narrative Review
Siôn A. Parry, Leanne Hodson Advances in Therapy.2020; 37(4): 1381. CrossRef -
Diabetes and Metabolism Journal in 2020: Good to Great
In-Kyung Jeong Diabetes & Metabolism Journal.2020; 44(1): 1. CrossRef - Non-Alcoholic Fatty Liver Disease in Patients with Type 2 Diabetes Mellitus: A Position Statement of the Fatty Liver Research Group of the Korean Diabetes Association
Byung-Wan Lee, Yong-ho Lee, Cheol-Young Park, Eun-Jung Rhee, Won-Young Lee, Nan-Hee Kim, Kyung Mook Choi, Keun-Gyu Park, Yeon-Kyung Choi, Bong-Soo Cha, Dae Ho Lee Diabetes & Metabolism Journal.2020; 44(3): 382. CrossRef - Molecular mechanisms of hepatic insulin resistance in nonalcoholic fatty liver disease and potential treatment strategies
Chang-hua Zhang, Bu-gao Zhou, Jun-qing Sheng, Yang Chen, Ying-qian Cao, Chen Chen Pharmacological Research.2020; 159: 104984. CrossRef - Beneficial effect of anti-diabetic drugs for nonalcoholic fatty liver disease
Kyung-Soo Kim, Byung-Wan Lee Clinical and Molecular Hepatology.2020; 26(4): 430. CrossRef - Effects of sodium–glucose cotransporter 2 inhibitors on non‐alcoholic fatty liver disease in patients with type 2 diabetes: A meta‐analysis of randomized controlled trials
Baodi Xing, Yuhang Zhao, Bingzi Dong, Yue Zhou, Wenshan Lv, Wenjuan Zhao Journal of Diabetes Investigation.2020; 11(5): 1238. CrossRef - Empaglifozin mitigates NAFLD in high-fat-fed mice by alleviating insulin resistance, lipogenesis and ER stress
Tamiris Ingrid Petito-da-Silva, Vanessa Souza-Mello, Sandra Barbosa-da-Silva Molecular and Cellular Endocrinology.2019; 498: 110539. CrossRef
|